Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

55
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
55
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

311
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
311
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.2K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.6K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

90
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
90
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

75
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
75

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide association study identifies <i>ABCG1</i> as a susceptibility locus for tick-borne encephalitis.

iScience·2025
Same author

Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case-control studies, 2015/16-2023/24.

BMC medicine·2025
Same author

[Diagnosis and treatment of hepatitis E virus: Guidelines of the Czech Society for Infectious Diseases].

Klinicka mikrobiologie a infekcni lekarstvi·2025
Same author

Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.

Influenza and other respiratory viruses·2025
Same author

[Pneumocystis pneumonia].

Klinicka mikrobiologie a infekcni lekarstvi·2025
Same author

[Cytomegalovirus coinfection].

Klinicka mikrobiologie a infekcni lekarstvi·2025

Related Experiment Video

Updated: Nov 11, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.1K

Current view on hepatitis B diagnosis and therapy.

Petr Husa

    Vnitrni Lekarstvi
    |March 23, 2021
    PubMed
    Summary

    Hepatitis B virus (HBV) infection is a global health issue. The safest way to stop nucleotide/nucleoside analogue therapy is by achieving HBsAg loss, indicating immune control.

    Area of Science:

    • Hepatology
    • Virology
    • Immunology

    Background:

    • Hepatitis B virus (HBV) infection presents evolving epidemiology globally, influenced by vaccination and migration.
    • Chronic Hepatitis B involves complex interactions between HBV replication and host immunity, not always manifesting as active liver disease.
    • Discontinuing nucleotide/nucleoside analogue (NA) therapy carries risks of viral reactivation, elevated HBV DNA, ALT, and liver inflammation.

    Purpose of the Study:

    • To identify the safest criterion for discontinuing nucleotide/nucleoside analogue therapy in chronic Hepatitis B patients.
    • To establish HBsAg loss as a reliable indicator of immune control for NA therapy cessation.

    Main Methods:

    • Review of epidemiological factors influencing HBV infection.
    • Analysis of the dynamics between HBV replication and host immune response in chronic infection.
    Keywords:
    chronic hepatitis Bentecavirstopping therapy.tenofovir

    More Related Videos

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.4K
    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
    09:35

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

    Published on: February 1, 2017

    13.6K

    Related Experiment Videos

    Last Updated: Nov 11, 2025

    Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
    04:11

    Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

    Published on: December 15, 2023

    4.1K
    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.4K
    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
    09:35

    Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

    Published on: February 1, 2017

    13.6K
  • Evaluation of risks associated with NA therapy cessation and identification of safe stopping rules.

    • Main Results:

    • HBsAg loss is identified as the safest marker for discontinuing NA therapy.
    • HBsAg loss signifies successful immune system control over HBV infection.

    Conclusions:

    • Achieving HBsAg loss is the optimal endpoint for NA therapy in chronic Hepatitis B.
    • Immune control, indicated by HBsAg loss, is crucial for safe and effective management of HBV infection.